scholarly journals Cord blood parameters change in pregnancy induced hypertension

2017 ◽  
Vol 5 (5) ◽  
pp. 2099 ◽  
Author(s):  
Purnima Meher ◽  
Sitanshu Kumar Meher ◽  
Sunil Kumar Jena
Keyword(s):  
Platelet Count ◽  
Cord Blood ◽  
Umbilical Cord ◽  
Absolute Neutrophil Count ◽  
Umbilical Cord Blood ◽  
Neutrophil Count ◽  
Reticulocyte Count ◽  
Pregnancy Induced Hypertension ◽  
Induced Hypertension ◽  
In Pregnancy

Background: Pregnancy induced hypertension (PIH) is a multisystem disease of unknown etiology which affects only human beings. It poses several problems to both mother and child. Complications in newborns like intrauterine death (IUD), intrauterine growth retardation (IUGR), perinatal asphyxia, neonatal sepsis and bleeding disorders are associated with toxaemia of pregnancy. To decrease the perinatal morbidity and mortality, babies of hypertensive mothers should be carefully monitored and managed. Aim of this study was to establish the changes in total platelet count, reticulocyte count and absolute neutrophil count of umbilical cord blood in pregnancy induced hypertension as compared to normotensive mothers.Methods: This case-control study was conducted among 60 subjects including 30 case (diagnosed cases of pregnancy induced hypertension) and 30 control (normotensive pregnant women). The case group was again categorized into three subgroups – gestational hypertension (06), pre-eclampsia (16) and eclampsia (08). In all the subjects, 2 ml of umbilical cord blood anticoagulated with EDTA was collected and haematological tests for reticulocyte count, total platelet count (TPC) and absolute neutrophil count was done.Results: There was significant decrease in TPC (p<0.01) and absolute neutrophil count (p<0.01), but significant rise in reticulocyte count (p<0.05) in umbilical cord blood of babies born to hypertensive mothers compared to normotensive mothersConclusions: From this study, it can be concluded that newborns of hypertensive mothers carry risks for infection and bleeding complications. So, these simple haematological tests can be done at early stage in neonates to reduce possible perinatal morbidities and mortality.

scholarly journals Resistin in pregnancy: analysis of determinants in pairs of umbilical cord blood and maternal serum

Cytokine X ◽  
2021 ◽  
pp. 100052
Author(s):  
Anne FLOECK ◽  
Nina FERRARI ◽  
Christine JOISTEN ◽  
Maria T. PUTH ◽  
Brigitte STRIZEK ◽  
...  
Keyword(s):  
Cord Blood ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Maternal Serum ◽  
In Pregnancy

DETECTION OF CORTICOSTEROIDS IN UMBILICAL CORD BLOOD IN PREGNANCY FOLLOWING ADRENALECTOMY

1962 ◽  
Vol 40 (3_Suppl) ◽  
pp. S110 ◽  
Author(s):  
V. H. T. James ◽  
E. Caie ◽  
P. H. Sanderson ◽  
G. Pinker
Keyword(s):  
Cord Blood ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
In Pregnancy

Chronic Graft Versus Host Disease (cGVHD) Following Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT): Higher Response Rate in Recipients of Unrelated Donor (URD) Umbilical Cord Blood (UCB).

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 1814-1814 ◽  
Author(s):  
Mukta Arora ◽  
Sriharsha Nagaraj ◽  
John E. Wagner ◽  
Juliet N. Barker ◽  
Claudio G. Brunstein ◽  
...  
Keyword(s):  
Platelet Count ◽  
Cord Blood ◽  
Umbilical Cord ◽  
Graft Versus Host Disease ◽  
Umbilical Cord Blood ◽  
Clinical Presentation ◽  
Response To Treatment ◽  
Liver Involvement ◽  
Unrelated Donor ◽  
Graft Versus Host

Abstract The nature of chronic graft versus host disease (cGVHD) after umbilical cord blood (UCB) transplant has not been well characterized. We analyzed clinical presentation and response to treatment in 170 patients with cGVHD (123 following transplant from an unrelated donor (URD) and 47 following transplant from UCB). URD transplant recipients were significantly younger (median age 25 (0.5–57) versus 39 (0.2–61) years, p = 0.002; and were less likely to receive a transplant from an HLA mismatched donor (33% versus 90%, p&lt;0.0001). Seven% and 43% of patients underwent a transplant using a non myeloablative conditioning in the URD and UCB groups, respectively (p&lt; 0.001). Progressive onset of cGVHD was seen in 27% and 19% of patients in URD and UCB cohorts (p =0.15) and platelet count of &lt; 100,000/μl was seen in 36% and 15% of patients (p =0.014), respectively. The median follow up was 5 (0.14–10.8) and 1.5 (0.02–8.8) years in the 2 groups, respectively. A higher rate of response (CR+PR) to treatment was seen in UCB group across all time periods. Rates of response were 48% versus 74% at 2 months (p =0.005); 49% versus 78% at 6 months (p =0.001) and 51% versus 72% at 1 year (p =0.03) in the URD and UCB groups, respectively. Overall survival at 2 years was 59% (50–67%) versus 71% (53–83%) at 2 years and at 5 years was 54% (44–63%) versus 64% (42–79%) (p=0.17). In multivariate analysis, progressive onset of CGVHD (RR=2.3, 95% CI 1.4–3.8−2.3,p=0.002), platelet count of &lt;100,000/μl (RR=3.5, 95% CI 1.7–7.3,p=0.0009), liver involvement (RR=2.5, 95% CI 1.4–4.6,p=0.002), and no CR or PR at 2 months (RR=3.5, 95% CI 2.1–5.9,p&lt;0.0001) were associated with significantly increased mortality. These data suggests that among patients undergoing transplant from unrelated donor or cord blood, despite similar clinical presentation, higher rates of response to treatment were seen in UCB recipients. Early identification of high risk groups (progressive onset, less than PR at 2 months, platelet count &lt; 100,000/μl and liver involvement should facilitate timely assignment of intensified therapy. Response to Treatment Response 2 mo 2 mo 6 mo 6 mo 1 year 1year URD UCB URD UCB URD UCB CR+PR 49 (48) 29 (74) 54 (49) 32 (78) 53 (51) 23 (72) SD+Prog 53 (52) 10 (26) 56 (51) 9 (22) 52 (49) 9 (28)

scholarly journals Human Serum PCSK9 Is Elevated at Parturition in Comparison to Nonpregnant Subjects While Serum PCSK9 from Umbilical Cord Blood is Lower Compared to Maternal Blood

2013 ◽  
Vol 2013 ◽  
pp. 1-8 ◽  
Author(s):  
Patricia Peticca ◽  
Angela Raymond ◽  
Andrée Gruslin ◽  
Marion Cousins ◽  
Ejibunmi Adetola ◽  
...  
Keyword(s):  
Cord Blood ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Serum Lipids ◽  
Physiological State ◽  
Ldl Receptor ◽  
Lipoprotein Metabolism ◽  
Density Lipoprotein ◽  
Maternal Blood ◽  
In Pregnancy

Background. Serum lipids including total cholesterol (TC), triglycerides (TG), and low density lipoprotein cholesterol (LDL-C) are increased in pregnancy. Serum proprotein convertase subtilisin kexin 9 (PCSK9) is a significant player in lipoprotein metabolism. Circulating PCSK9 downregulates the LDL receptor on the surface of the liver, inhibiting clearance of LDL-C. Therefore, our study assessed serum PCSK9 concentrations at parturition (Maternal) compared to a nonpregnant (Control) cohort, as well as between mother and newborn (Maternal and Newborn). Methods. Blood was collected from women at parturition and from umbilical cords. Serum lipids and PCSK9 were measured and data were analysed for significance by Mann-Whitney U test at P<0.05 and presented as median levels. Spearman's correlations were made at a 95% confidence interval. Results. Serum PCSK9 was significantly higher in Maternal versus Control cohorts (493.1 versus 289.7 ng/mL; P<0.001, resp.), while the Newborn cohort was significantly lower than Maternal (278.2 versus 493.1 ng/mL; P<0.0001, resp.). PCSK9 was significantly correlated with TC and HDL-C in Maternal and with TC, LDL-C, and HDL-C in Newborn cohorts. Conclusions. Our study provides the first quantitative report on PCSK9 in pregnancy (at parturition) and in umbilical cord blood. Further research will determine how these changes may affect lipoprotein levels during this physiological state.

Sign in / Sign up

Export Citation Format

Share Document